EGFR and non-small cell lung carcinoma: Briefly, in this study, afatinib first-line treatment was found to have encouraging efficacy in brain metastases in advanced NSCLC patients harboring either common or major uncommon EGFR mutations in a real-world setting, with manageable toxicities.